JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2002; 40:1723-1730
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bellamy, M. F.
Right arrow Articles by Enriquez-Sarano, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellamy, M. F.
Right arrow Articles by Enriquez-Sarano, M.

Association of cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase inhibitor treatment, and progression of aortic stenosis in the community

Michael F. Bellamy, MD, MRCP*, Patricia A. Pellikka, MD, FACC*, Kyle W. Klarich, MD, FACC*, A. Jamil Tajik, MD, FACC* and Maurice Enriquez-Sarano, MD, FACC*,*

* Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA



View larger version (23K):

[in a new window]
  		Figure 1 Annualized progression in mean gradient (Mean Grad), peak velocity (Vmax), and aortic valve area (AVA) by quartile of total cholesterol (TChol) concentration in subjects not receiving lipid-lowering treatment. The circles and vertical bars indicate means and standard errors. BSA = body surface area.

 


View larger version (22K):

[in a new window]
  		Figure 2 Association of statin treatment with slower progression of aortic stenosis (AS) as shown by odds ratios and 95% confidence intervals <1 for criteria of progression. The odds ratios are indicated by the circles (for the overall population) and by squares (for patients with systematic follow-up [F-U] not motivated by symptomatic progression) with their 95% confidence interval (continuous and dashed line, respectively). Progression criteria are defined by median in the population for (top to bottom) mean gradient (Mean grad), peak transaortic velocity (Vmax), dimensionless index (Index), aortic valve area (AVA), and aortic valve area standardized to body surface area (AVA/BSA). The directions of the changes are indicated by the arrows: upward for increases, downward for decreases.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2002 by the American College of Cardiology Foundation.